SLNO — Soleno Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
Soleno Therapeutics Inc (SLNO) is a biotechnology company listed on NASDAQ. It is led by Anish Bhatnagar M.D., based in 100 Marine Parkway, Redwood City, CA, United States, 94065, with about 182 employees. Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. As of May 18, 2026, Soleno Therapeutics, Inc. operates as a subsidiary of Neurocrine Biosciences, Inc.
Net income was -$22.5M. SLNO currently screens at market cap $2.76B and trailing P/E 27.5.
Use this SLNO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SLNO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SLNO SEC filings page. Lician reads the product cache first so this HTML stays unique to Soleno Therapeutics Inc even when a live quote feed is slow.
About Soleno Therapeutics Inc
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. As of May 18, 2026, Soleno Therapeutics, Inc. operates as a subsidiary of Neurocrine Biosciences, Inc.
SLNO Key Statistics
Market Cap
$2.76B
P/E Ratio
27.47
P/B Ratio
5.57
EPS
-$4.38
Revenue
$0.00
Net Income
-$175.85M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
182
SLNO Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$175.85M | -$38.99M | -$24.07M | -$30.91M |
| EPS (Diluted) | -$4.38 | -$2.36 | -$2.87 | -$5.81 |
Total Assets
$330.97M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$87.93M
Operating Cash Flow
-$69.10M
Free Cash Flow
$0.00
Soleno Therapeutics Inc Company Information
- Chairman, President & CEO
- Anish Bhatnagar M.D.
- Headquarters
- 100 Marine Parkway, Redwood City, CA, United States, 94065
- Website
- soleno.life
- Phone
- 650 213 8444
- IPO / Founded
- 2014-11-13
- Sector
- Healthcare
- Industry
- Biotechnology